Journal of Developing Drugs
Open Access
ISSN: 2329-6631
+44 1478 350008
ISSN: 2329-6631
+44 1478 350008
Massimo Serra
Chief of Pharmacogenomics and Pharmacogenetics, Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute
Italy
Massimo Serra got the Degree in Biological Sciences (score of 110 out of 110, with high honours). Since 1989, he is employed as Staff Researcher (Biologo Dirigente I Livello) at the Laboratory of Experimental Oncology of the Orthopaedic Rizzoli Institute, I.R.C.C.S.(Bologna, Italy). He also worked abroad as Research Fellow at the "Molecular Genetics Laboratory" (Salk Institute, San Diego, CA) in 1993 and as Research Fellow at the "Cytogenetics and Molecular Genetics Laboratory" of the University of Helsinki (Finland) in 1997. From 1999 to 2008, he has been the Chief of the "Drug Resistance" Research Unit (Modulo Organizzativo), which was upgraded to the "Pharmacogenomics and Pharmacogenetics" Research Unit (Struttura Semplice) on 2009, at the Laboratory of Experimental Oncology of the Orthopaedic Rizzoli Institute. From 1998 to 2008, he has been member of the Scientific Committee of the Orthopaedic Rizzoli Institute and of the Directive Committee of the Musculo-Skeletal Oncology, department of the Orthopaedic Rizzoli Institute. Since 2009, he is member of the Direction Committee of the Orthopaedic Rizzoli Institute.
•Analysis of the genetic and molecular mechanisms responsible for drug resistance in the most common bone and soft-tissue sarcomas, as well as on the genetic background associated with a differential drug sensitivity in osteosarcoma.
•Pharmacogenomic and pharmacogenetic characterisation of the most common musculoskeletal tumours, with particular regard to osteosarcoma.
•Analysis of genetic and molecular mechanisms responsible for resistance to doxorubicin, methotrexate and cisplatin in human osteosarcoma cells.
•Preclinical validation of candidate prognostic and therapeutic markers in osteosarcoma and other bone tumor patients.
•Preclinical evaluation of the efficacy of new target-specific drugs and innovative therapeutic approaches for osteosarcoma and analysis of their interactions with conventional chemotherapeutic drugs and regimens.